Research that Identifies
Undiscovered Value in the MicroCap Market



ZYNEX, INC.

Zynex, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Updated Research Report (Dated 11/20/2017)

Symbol: ZYXI
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $5.00
Time Horizon: 12 Months
Rating Established: August 21, 2017
Price When Established: $1.08
Most Recent Report: November 20, 2017
Price When Issued: $3.06


What's New

Zynex Reports Preliminary 4Q17 Revenue

On January 8, 2018, Zynex, Inc. reported preliminary revenues for its fourth quarter of fiscal 2017, ended December 31, 2017.

ZYXI expects to report revenue between $7.5 million and $8 million, up from $2.9 million in the year-ago period.

Our current forecast calls for fourth quarter 2017 revenue of $7.1 million.


Zynex Medical Announces Share Buyback

On December 6, 2017, Zynex Medical announced that its board of directors approved a $2 million stock buyback program.

Under the share buyback program, buybacks may be made from time-to-time in open market and negotiated purchases, effective immediately through the next twelve months.


Company Description

Zynex, Inc., headquartered in Lone Tree, Colorado provides FDA-cleared electrotherapy medical devices used for pain management and rehabilitation. The company is primarily focused on selling and marketing its NexWave and InWave electrotherapy product, as well as consumable supplies for electrotherapy products. The company operates two subsidiaries, Zynex Medical™, which provides electrotherapy devices and consumable products for home use and Zynex Monitoring Solutions™, which is developing a blood volume-monitoring device for use in hospitals and outpatient surgical centers.


Company Reports

Updated Research Report (Dated November 20, 2017)

Initial Research Report (Dated July 26, 2017)


Disclaimer

Please view our current disclosure and disclaimer on our most recent research report.